ALKS vs PATH
Alkermes Plc (ALKS) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Alkermes Plc (ALKS) is a drug manufacturers - specialty & generic company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported ALKS revenue for 2024-12-31 was $1.56B. Net income was $367.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. ALKS currently screens at market cap $4.78B and trailing P/E 13.8.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
ALKS currently screens at market cap $4.78B and trailing P/E 13.8. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the ALKS and PATH stock pages for the full models.
Not investment advice.